AcelRx Pharmaceuticals (ACRX) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
AcelRx Pharmaceuticals (NASDAQ:ACRX) announced its earnings results on Monday. The company reported ($0.24) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.26) by $0.02, StockRatingsNetwork reports.
AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down 0.31% during mid-day trading on Monday, hitting $6.45. The stock had a trading volume of 635,119 shares. AcelRx Pharmaceuticals has a 52-week low of $6.04 and a 52-week high of $13.64. The stock’s 50-day moving average is $9.28 and its 200-day moving average is $10.43. The company’s market cap is $279.4 million.
A number of analysts have recently weighed in on ACRX shares. Analysts at Cowen and Company reiterated an “outperform” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, July 29th. They now have a $14.00 price target on the stock, down previously from $15.00. On a related note, analysts at Piper Jaffray downgraded shares of AcelRx Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 29th. They now have a $8.00 price target on the stock, down previously from $14.00. Finally, analysts at JMP Securities cut their price target on shares of AcelRx Pharmaceuticals from $14.00 to $12.00 in a research note on Monday, July 28th. They now have an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $13.17.
AcelRx Pharmaceuticals, Inc is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.